Biological Products, (No Diagnostic Substances)
Standard Industrial Classification: SIC 2836
Industry Insider Sentiment Analysis
The Biological Products, (No Diagnostic Substances) sector (SIC 2836) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-17 01:33 | 2026-11-12 | HALO | HALOZYME THERAPEUTICS, INC. | Torley Helen | Director, Officer | OPT+S | $100.01 | 60,000 | $6,000,684 | 767,780 |
| 2026-11-16 21:05 | 2026-11-12 | TWST | Twist Bioscience Corp | Green Paula | Officer | SELL | $0.00 | 20,429 | $0 | 126,054 |
| 2026-11-16 21:05 | 2026-11-13 | FENC | FENNEC PHARMACEUTICALS INC. | Brughera Marco Maria | Director | OPT+S | $12.00 | 20,000 | $240,000 | 0 |
| 2026-11-16 20:32 | 2026-11-12 | GILD | GILEAD SCIENCES, INC. | Kramer Kelly A. | Director | OPT+S | $169.76 | 10,376 | $1,761,437 | 1,339 |
| 2026-11-16 11:43 | 2026-11-13 | AGMB | AgomAb Therapeutics NV | Epstein David R | Director | BUY | $5.92 | 14,980 | $88,679 | 54,980 |
| 2026-11-13 21:10 | 2026-11-12 | CCCC | C4 Therapeutics, Inc. | Adams Kendra | Officer | SELL | $2.71 | 45,173 | $122,487 | 337,150 |
| 2026-11-14 00:56 | 2026-11-11 | ADPT | Adaptive Biotechnologies Corp | BOBULSKY SUSAN | Officer | SELL | $32.00 | 1,875 | $60,000 | 387,475 |
| 2026-11-14 00:59 | 2026-11-11 | ADPT | Adaptive Biotechnologies Corp | RUBINSTEIN JULIE | Officer | OPT+S | $29.73 | 35,228 | $1,047,304 | 377,802 |
| 2026-11-13 23:00 | 2026-11-11 | RVMD | Revolution Medicines, Inc. | Anders Jack | Officer | OPT+S | $188.10 | 35,750 | $6,724,689 | 119,216 |
| 2026-11-13 21:32 | 2026-11-11 | EDIT | Editas Medicine, Inc. | Burkly Linda | Officer | SELL | $2.42 | 7,814 | $18,875 | 70,379 |
| 2026-11-13 21:34 | 2026-11-11 | EDIT | Editas Medicine, Inc. | O'Neill Gilmore Neil | Director, Officer | SELL | $2.42 | 21,164 | $51,122 | 265,592 |
| 2026-11-13 21:09 | 2026-11-11 | PCVX | Vaxcyte, Inc. | Dhaliwal Harpreet S. | Officer | OPT+S | $67.83 | 17,000 | $1,153,103 | 68,085 |
| 2026-11-13 13:00 | 2026-11-11 | AIM | AIM ImmunoTech Inc. | Equels Thomas K | Director, Officer | BUY | $0.15 | 35,000 | $5,215 | 328,095 |
| 2026-11-12 21:11 | 2026-11-10 | DTIL | PRECISION BIOSCIENCES INC | Scimeca Dario | Officer | SELL | $9.75 | 2,821 | $27,505 | 56,782 |
| 2026-11-13 01:04 | 2026-11-09 | VCEL | Vericel Corp | Mara Joseph Anthony Jr | Officer | OPT+S | $58.26 | 25,008 | $1,456,979 | 16,186 |
| 2026-11-13 00:43 | 2026-11-09 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | OPT+S | $57.88 | 2,000 | $115,760 | 32,995 |
| 2026-11-13 00:48 | 2026-11-10 | VCEL | Vericel Corp | MCLAUGHLIN KEVIN F | Director | OPT+S | $58.96 | 7,000 | $412,720 | 18,300 |
| 2026-11-12 23:00 | 2026-11-09 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | Officer | OPT+S | $200.00 | 811 | $162,200 | 39,765 |
| 2026-11-12 21:41 | 2026-11-11 | IMVT | Immunovant, Inc. | Pande Atul | Director | OPT+S | $36.00 | 3,000 | $108,000 | 116,731 |
| 2026-11-12 13:00 | 2026-11-10 | AIM | AIM ImmunoTech Inc. | Equels Thomas K | Director, Officer | BUY | $0.14 | 39,000 | $5,382 | 293,095 |
| 2026-11-11 01:09 | 2026-11-06 | ETRA | Electra Therapeutics, Inc. | ORBIMED ADVISORS LLC | Director, 10% owner | BUY | $8.08 | 92,116 | $744,528 | 2,194,579 |
| 2026-11-11 01:14 | 2026-11-06 | ETRA | Electra Therapeutics, Inc. | GORDON CARL L | Director, 10% owner | BUY | $8.08 | 92,116 | $744,528 | 2,194,579 |
| 2026-11-11 00:26 | 2026-11-09 | ADPT | Adaptive Biotechnologies Corp | RUBINSTEIN JULIE | Officer | OPT+S | $29.82 | 23,762 | $708,557 | 377,802 |
| 2026-11-10 21:30 | 2026-11-09 | REPL | Replimune Group, Inc. | SLATTERY JOSEPH P | Director | SELL | $21.80 | 5,200 | $113,360 | 1,467 |
| 2026-11-10 15:07 | 2026-11-09 | AIM | AIM ImmunoTech Inc. | Equels Thomas K | Director, Officer | BUY | $0.16 | 31,298 | $5,070 | 254,095 |
| 2026-11-10 00:20 | 2026-11-06 | GILD | GILEAD SCIENCES, INC. | Cain Wettan Keeley M | Officer | SELL | $164.11 | 3,399 | $557,810 | 5,360 |
| 2026-11-09 21:05 | 2026-11-05 | VCEL | Vericel Corp | Mara Joseph Anthony Jr | Officer | OPT+S | $53.48 | 50,000 | $2,674,020 | 16,186 |
| 2026-11-09 20:47 | 2026-11-06 | AIM | AIM ImmunoTech Inc. | Equels Thomas K | Director, Officer | BUY | $0.16 | 12,751 | $2,015 | 222,797 |
| 2026-11-07 00:24 | 2026-11-04 | ADPT | Adaptive Biotechnologies Corp | RUBINSTEIN JULIE | Officer | OPT+S | $26.78 | 35,643 | $954,441 | 377,802 |
| 2026-11-06 22:15 | 2026-11-04 | GILD | GILEAD SCIENCES, INC. | O'Day Daniel Patrick | Director, Officer | OPT+S | $175.16 | 112,429 | $19,693,435 | 551,683 |
| 2026-11-06 21:55 | 2026-11-04 | KOD | Kodiak Sciences Inc. | BAKER BROS. ADVISORS LP | Director, 10% owner | BUY | $98.51 | 247,090 | $24,340,836 | 20,424,859 |
| 2026-11-06 22:00 | 2026-11-05 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Officer | OPT+S | $12.36 | 4,000 | $49,440 | 158,649 |
| 2026-11-06 21:05 | 2026-11-04 | VCEL | Vericel Corp | ZERBE ROBERT L MD | Director | OPT+S | $49.12 | 5,500 | $270,175 | 32,995 |
| 2026-11-06 21:05 | 2026-11-05 | VCEL | Vericel Corp | Flynn Sean C. | Officer | OPT+S | $51.92 | 15,000 | $778,800 | 1,990 |
| 2026-11-06 21:05 | 2026-11-05 | VCEL | Vericel Corp | SIEGAL JONATHAN | Officer | OPT+S | $52.90 | 1,500 | $79,350 | 1,259 |
| 2026-11-06 18:58 | 2026-11-06 | AIM | AIM ImmunoTech Inc. | Equels Thomas K | Director, Officer | BUY | $0.16 | 20,299 | $3,167 | 210,046 |
| 2026-11-06 11:39 | 2026-11-05 | AGMB | AgomAb Therapeutics NV | Epstein David R | Director | BUY | $6.90 | 15,000 | $103,500 | 40,000 |
| 2026-11-05 21:10 | 2026-11-03 | IPSC | Century Therapeutics, Inc. | Carr Douglas | Officer | SELL | $1.52 | 266 | $404 | 502,641 |
| 2026-11-06 02:05 | 2026-11-05 | ADMA | ADMA BIOLOGICS, INC. | Grossman Adam S | Director, Officer | OPT+S | $12.00 | 147,000 | $1,764,000 | 2,070,777 |
| 2026-11-05 22:47 | 2026-11-03 | ETRA | Electra Therapeutics, Inc. | GORDON CARL L | Director, 10% owner | BUY | $7.63 | 472,571 | $3,605,102 | 2,136,979 |
| 2026-11-05 22:39 | 2026-11-03 | ETRA | Electra Therapeutics, Inc. | ORBIMED ADVISORS LLC | Director, 10% owner | BUY | $7.63 | 472,571 | $3,605,102 | 2,136,979 |
| 2026-11-05 21:05 | 2026-11-03 | TWST | Twist Bioscience Corp | Green Paula | Officer | SELL | $135.40 | 1,007 | $136,350 | 105,625 |
| 2026-11-05 21:05 | 2026-11-03 | TWST | Twist Bioscience Corp | WERNER ROBERT F. | Officer | SELL | $135.40 | 148 | $20,039 | 42,769 |
| 2026-11-05 21:05 | 2026-11-03 | TWST | Twist Bioscience Corp | Leproust Emily M. | Director, Officer | SELL | $135.40 | 4,573 | $619,193 | 558,187 |
| 2026-11-05 21:05 | 2026-11-03 | TWST | Twist Bioscience Corp | Finn Patrick John | Officer | SELL | $135.40 | 2,565 | $347,306 | 180,278 |
| 2026-11-05 21:05 | 2026-11-03 | TWST | Twist Bioscience Corp | Cho Dennis | Officer | SELL | $135.40 | 949 | $128,496 | 62,840 |
| 2026-11-04 21:13 | 2026-11-02 | MAZE | Maze Therapeutics, Inc. | Coloma Jason V | Director, Officer | SELL | $30.25 | 34,501 | $1,043,766 | 186,901 |
| 2026-11-04 22:12 | 2026-11-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Borgeson Blake | Director | SELL | $3.88 | 40,000 | $155,200 | 6,068,287 |
| 2026-11-04 22:12 | 2026-11-02 | LYCA | Lycia Therapeutics, Inc. | Venrock Healthcare Capital Partners III, L.P. | 10% owner | BUY | $26.95 | 8,305 | $223,820 | 6,858,542 |
| 2026-11-04 21:51 | 2026-11-02 | PCVX | Vaxcyte, Inc. | Wassil Jim | Officer | OPT+S | $60.90 | 2,250 | $137,024 | 145,435 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Biological Products, (No Diagnostic Substances) sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2836) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Biological Products, (No Diagnostic Substances)
Every transaction in the Biological Products, (No Diagnostic Substances) industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.